HUTCHMED DRC
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at HUTCHMED DRC.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 10.00 $ to 16.40 $ · Last price: 13.90 $ (As of: September 25, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/25/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Drug Manufacturers - Specialty & Generic
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| HUTCHMED DRC HCM | 2.4 | 138.7 | 2.3 | 13.3 | 0.3 | -12.7 | -12.5 |
| Takeda Pharmaceutical Co Ltd TAK | 60.3 | – | 23.4 | 64.5 | 16.5 | 4.3 | 29.3 |
| Teva Pharma Industries Ltd TEVA | 45.7 | 65.3 | 18.9 | 52.5 | 4.0 | 4.3 | 108.7 |
| Zoetis Inc ZTS | 30.0 | 11.9 | 9.2 | 71.7 | 36.6 | 2.3 | -49.5 |
| Viatris Inc VTRS | 20.2 | – | 11.9 | 40.3 | 6.8 | -3.0 | 94.5 |
| United Therapeutics Corporation UTHR | 20.2 | 17.2 | 10.9 | 86.1 | 41.7 | 10.6 | 11.8 |
| Neurocrine Biosciences Inc NBIX | 13.9 | 22.0 | 15.7 | 64.5 | 22.8 | 21.5 | -1.8 |
| Elanco Animal Health ELAN | 11.1 | – | 18.9 | 55.4 | 12.3 | 6.2 | 17.9 |
| Dr. Reddy’s Laboratories Ltd RDY | 10.2 | 29.2 | 14.5 | 50.2 | 4.3 | 8.6 | -14.0 |
| Median of companies shown | 20.2 | 25.6 | 14.5 | 55.4 | 12.3 | 4.3 | 11.8 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 216 | -47 | 12 | 0.10 | -10 | 184 | 342 |
| 2017 | 241 | -53 | -27 | -0.22 | -9 | 462 | 598 |
| 2018 | 214 | -93 | -75 | -0.56 | -33 | 389 | 532 |
| 2019 | 205 | -153 | -106 | -0.80 | -81 | 288 | 465 |
| 2020 | 228 | -199 | -126 | -4.51 | -62 | 484 | 724 |
| 2021 | 356 | -357 | -195 | -1.23 | -204 | 987 | 1,373 |
| 2022 | 426 | -719 | -361 | -2.13 | -269 | 610 | 1,029 |
| 2023 | 838 | 18 | 101 | 0.58 | 219 | 731 | 1,280 |
| 2024 | 630 | -44 | 38 | 0.22 | 1 | 760 | 1,274 |
| 2025 | 550 | -55 | 458 | 2.62 | -65 | 1,238 | 1,753 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q3 | 0.00 | – | 162 | 102.20 | 3.70 | 20 | 16 |
| 2024: Q4 | 0.01 | 101.40 | 162 | 6.40 | 3.70 | 20 | 16 |
| 2025: Q1 | 0.00 | – | 139 | -9.20 | 163.80 | -36 | -41 |
| 2025: Q2 | 0.52 | – | 139 | -9.20 | 163.80 | -36 | -41 |
| 2025: Q3 | 0.00 | – | 135 | -16.50 | 0.70 | 4 | 2 |
| 2025: Q4 | – | – | 135 | -16.50 | 0.70 | 4 | 2 |
| 2026: Q1 | – | – | 139 | 0.20 | 5.70 | 6 | 3 |
| 2026: Q2 | – | – | 139 | 0.20 | 5.70 | 6 | 3 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 2 of our scanner strategies — each hit links to the scanner.
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.20 | 0.03 – 0.40 | 630 | -92.5% | 5 |
| 12/31/2027 | 0.26 | 0.07 – 0.62 | 722 | 33.0% | 6 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Instead of guessing what the stock is worth, we turn the question around: what free cash flow growth has to happen for today’s market value to add up? The assumptions behind it can be moved.
Today’s market value implies roughly 42.9% growth in free cash flow per year over ten years (assumptions: discount rate 10.0%, terminal growth 2.5%).
| Free cash flow (last twelve months) | $9.9M |
|---|---|
| Market cap | $2.41B |
| Free cash flow in year ten | $353.0M |
| Terminal value as a share of market value | 77.2% |
It shows which assumption is built into today’s price, not whether that assumption will hold. Every assumption can be changed with the sliders; the figures move with them.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 8.9%
- More than 10% revenue growth is expected for the coming year 10.9%
- Share count grows by less than 3% a year 1.0%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -28.9%
- Gross margin at 40% or higher and without meaningful erosion 38.7%
- Goodwill from acquisitions does not grow faster than revenue 0.2%
- Net debt below twice EBITDA 1,269 m net cash
- Operating cash flow covers the profits of the last three years -442 m
- Return on capital at 15% or higher, or up versus two years ago -3.8%
- Insiders hold at least 10% or are net buyers 0.0%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
4/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 10.9%
- Exp. sales growth 3Y > 5% 14.6%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% -68.5%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 1
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% 37.4%
- ROCE > 15% -3.8%
- Expected return > 10% -69.6%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
The company
About the Company
HUTCHMED (China) Limited erforscht, entwickelt und vermarktet zusammen mit ihren Tochtergesellschaften zielgerichtete Therapeutika und Immuntherapien zur Behandlung von Krebs und Immunerkrankungen in Hongkong, den Vereinigten Staaten und international. Das Unternehmen bietet Fruquintinib, einen selektiven und potenten oralen Inhibitor der Rezeptoren des vaskulären endothelialen Wachstumsfaktors, zur Behandlung von Kolorektalkarzinom (CRC), Brustkrebs, Magenkrebs (GC), mikrosatellitenstabilem endometrialem CRC (EMC), nicht-kleinzelligem Lungenkarzinom (NSCLC), Nierenzellkarzinom (RCC) sowie Endometriumkarzinom (EMC); sowie Savolitinib, einen potenten und selektiven Inhibitor des mesenchymal-epithelialen Übergangsrezeptors zur Behandlung von NSCLC, papillärem RCC und GC. Es entwickelt außerdem Surufatinib zur Behandlung von pankreatischen neuroendokrinen Tumoren (NET), nicht-pankreatischen NET und duktalem Pankreasadenokarzinom; Sovleplenib zur Behandlung von immunthrombozytopenischer Purpura und wärmereaktiver autoimmuner hämolytischer Anämie; sowie Tazemetostat, eine Behandlung für epitheloides Sarkom und follikuläres Lymphom; Fanregratinib zur Behandlung des intrahepatischen Cholangiokarzinoms; und Ranosidenib, einen neuartigen Doppelinhibitor der Enzyme Dehydrogenase-1 und Isocitrat-Dehydrogenase-2 zur Behandlung der akuten myeloischen Leukämie (AML). Darüber hinaus entwickelt das Unternehmen HMPL-760, das sich in Phase-I/II-Studien zur Behandlung des rezidivierten und/oder refraktären diffusen großzelligen B-Zell-Lymphoms, der chronischen lymphatischen Leukämie, des kleinzelligen lymphozytischen Lymphoms und anderer B-NHL befindet; sowie HMPL-506 zur Behandlung von Mixed-lineage-Leukämie-Rearrangement und Nucleophosmin-1-mutierter AML. Es unterhält Kooperationsvereinbarungen mit AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc. sowie Epizyme, Inc. Das Unternehmen hieß früher Hutchison China MediTech Limited und änderte seinen Namen im Mai 2021 in HUTCHMED (China) Limited. HUTCHMED (China) Limited wurde 2000 gegründet und hat seinen Hauptsitz in Hongkong, Hongkong.
- Employees
- 1,790
- Headquarters
- Hong Kong, Hong Kong
- Address
- Cheung Kong Center, Hong Kong, Hong Kong
- Phone
- 852 2121 8200
- Website
- hutch-med.com
- IPO Date
- 03/17/2016
- ISIN
- US44842L1035
- Stock Split
- 10:1 on 05/30/2019
Management
| Name | Title | Birth Year |
|---|---|---|
| Chig Fung Cheng BEc, CA | Acting CEO, CFO & Executive Director | 1967 |
| Wei-Guo Su B.Sc., Ph.D. | CEO, Chief Scientific Officer & Executive Director (Leave of Absence) | 1959 |
| Yiling Cui | Executive VP & Head of Operations | – |
| Xinhui Hu Ph.D. | Executive Vice President & Chief Technical Officer | 1973 |
| David Ng | Head of Investor Relations & Capital Strategies | – |
| Charles George Rupert Nixon | Group General Counsel | 1970 |
| Kin Hung Lee M.B.A. | Senior Vice President of Corporate Management & Communications | 1977 |
| Selina Zhang | Senior Vice President of Global Human Resources | – |
| Qingmei Wang Ph.D. | Executive Vice President of Business Development & Strategic Alliances | 1963 |
| Thomas Fu | Senior Vice President of Global Quality | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.